Paul Andrew Moore, Chief Scientific Officer of Zymeworks Inc. ($ZYME), sold shares on the open market three times in the last year for a total of $721 thousand. His most recent ZYME insider sale occurred on January 12, 2026. These open market sales rank 5,661st among 11,678 insiders, below the average of $8.6 million across 6.4 transactions. Moore made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 9560 | $22.67 | 48,497.0000 | 75,775,214 | 16.47% | 0.01% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 17666 | $0.00 | 58,057.0000 | 75,775,214 | 43.74% | 0.02% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Performance Stock Unit | 66000 | $0.00 | 66,000.0000 | 75,775,214 | 9999.99% | 0.09% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Restricted Stock Unit | 47000 | $0.00 | 47,000.0000 | 75,775,214 | 9999.99% | 0.06% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Stock Option (Right to Buy) | 70000 | $0.00 | 70,000.0000 | 75,775,214 | 9999.99% | 0.09% |
| Jan. 12, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 17666 | $0.00 | 35,334.0000 | 75,775,214 | 33.33% | 0.02% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 20000 | $0.00 | 51,212.0000 | 75,775,214 | 64.08% | 0.03% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 17168 | $0.00 | 40,501.0000 | 75,775,214 | 73.58% | 0.02% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 20000 | $0.00 | 20,000.0000 | 75,775,214 | 50.00% | 0.03% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 17168 | $0.00 | 0.0000 | 75,775,214 | 100.00% | 0.02% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 10821 | $25.10 | 40,391.0000 | 75,775,214 | 21.13% | 0.01% |
| Jan. 5, 2026 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 9289 | $25.10 | 31,212.0000 | 75,775,214 | 22.94% | 0.01% |
| Jan. 10, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Stock Option (Right to Buy) | 79000 | $0.00 | 79,000.0000 | 75,878,738 | 9999.99% | 0.10% |
| Jan. 10, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Restricted Stock Unit | 53000 | $0.00 | 53,000.0000 | 75,878,738 | 9999.99% | 0.07% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 17166 | $0.00 | 24,533.0000 | 75,878,738 | 233.01% | 0.02% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 9792 | $14.92 | 14,741.0000 | 75,878,738 | 39.91% | 0.01% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 20000 | $0.00 | 40,000.0000 | 75,878,738 | 33.33% | 0.03% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 17166 | $0.00 | 17,168.0000 | 75,878,738 | 50.00% | 0.02% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 11408 | $14.92 | 23,333.0000 | 75,878,738 | 32.84% | 0.02% |
| Jan. 6, 2025 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 20000 | $0.00 | 34,741.0000 | 75,878,738 | 135.68% | 0.03% |
| Jan. 5, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Common Stock | 17166 | $0.00 | 17,166.0000 | 68,863,010 | 9999.99% | 0.02% |
| Jan. 5, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Restricted Stock Unit | 60000 | $0.00 | 60,000.0000 | 68,863,010 | 9999.99% | 0.09% |
| Jan. 5, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 68,863,010 | 9999.99% | 0.13% |
| Jan. 5, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | M | Restricted Stock Unit | 17166 | $0.00 | 34,334.0000 | 68,863,010 | 33.33% | 0.02% |
| Jan. 8, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 2339 | $11.22 | 7,367.0000 | 68,863,010 | 24.10% | 0.00% |
| Jan. 5, 2024 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | S | Common Stock | 7460 | $10.65 | 9,706.0000 | 68,863,010 | 43.46% | 0.01% |
| Jan. 5, 2023 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Stock Option (Right to Buy) | 77500 | $0.00 | 77,500.0000 | 65,249,184 | 9999.99% | 0.12% |
| Jan. 5, 2023 | Zymeworks Inc. | $ZYME | Moore Paul Andrew | Chief Scientific Officer | A | Restricted Stock Unit | 51500 | $0.00 | 51,500.0000 | 65,249,184 | 9999.99% | 0.08% |